Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Melanie Gloria departed as Chief Operating Officer at ACELYRIN, Inc..
- Action
- stepped down
- Role
- Chief Operating Officer
Exact text from the filing
On Augus t 9, 2024, the Company and Melanie Gloria mutually agreed that Ms. Gloria will step down from her position as Chief Operating Officer of the Company, effective October 31, 2024.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
ACELYRIN, Inc. announced a restructuring with charges of approximately $4.5 million in cash-based expenses related to employee severance payments and benefits affecting enterprise (workforce reduction associated with focus on lonigutamab clinical program) (approximately 40 people, or approximately 1/3 of the Company's existing headcount).
- Type
- restructuring
- Charge
- approximately $4.5 million in cash-based expenses related to employee severance payments and benefits
- Affected area
- enterprise (workforce reduction associated with focus on lonigutamab clinical program)
- Headcount
- approximately 40 people, or approximately 1/3 of the Company's existing headcount
Exact text from the filing
the Company will focus its efforts primarily on its lonigutamab clinical program in thyroid eye disease and will implement an associated workforce reduction (the “Restructuring Plan”). As part of the Restructuring Plan, the Company’s workforce will be reduced by approximately 40 people, or approximately 1/3 of the Company’s existing headcount. The Company expects to incur charges related to the Restructuring Plan. In this regard, the Company estimates that it will incur approximately $4.5 million in cash-based expenses related to employee severance payments and benefits related to the workforce reduction.
View on SEC.gov